Abeona Therapeutics Inc ABEO:NASDAQ

RT Quote | NASDAQ | USD
Last | 08/18/22 EDT
4.36quote price arrow down-0.24 (-5.22%)
Volume
111,019
52 week range
3.26 - 34.00
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.36
  • 52 Week High34.00
  • 52 Week High Date09/07/21
  • 52 Week Low3.26
  • 52 Week Low Date05/11/22

Key Stats

  • Market Cap25.94M
  • Shares Out5.95M
  • 10 Day Average Volume0.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-48.25

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close4.36
  • 52 Week High34.00
  • 52 Week High Date09/07/21
  • 52 Week Low3.26
  • 52 Week Low Date05/11/22
  • Market Cap25.94M
  • Shares Out5.95M
  • 10 Day Average Volume0.45M
  • Dividend-
  • Dividend Yield-
  • Beta1.11
  • YTD % Change-48.25

RATIOS/PROFITABILITY

  • EPS (TTM)-18.58
  • P/E (TTM)-0.23
  • Fwd P/E (NTM)-0.97
  • EBITDA (TTM)-49.756M
  • ROE (TTM)-166.25%
  • Revenue (TTM)4.35M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,905.50%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/14/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Abeona Therapeutics Inc

There is no recent news for this security.

Profile

MORE
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops gene and cell therapies for life-threatening rare genetic diseases. The Company’s lead clinical programs consist of EB-101, which is an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa (RDEB) and ABO-102, which is an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company is focused on to develop additional...
Michael Amoroso
Chairman of the Board
Vishwas Seshadri Ph.D.
President, Chief Executive Officer, Director
Joseph Vazzano CPA
Chief Financial Officer, Chief Accounting Officer
Brendan O Malley J.D., Ph.D.
General Counsel
Address
1330 Avenue of the Americas Fl 33
New York, NY
10019-5442
United States